Praxis Precision Medicines, Inc. Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Praxis Precision Medicines, Inc. has an operating margin of -2340.3%, meaning the company retains $-2340 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -5164.4% the prior year.
Praxis Precision Medicines, Inc.'s revenue surged 249.5% year-over-year to $8.6M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Praxis Precision Medicines, Inc. carries a low D/E ratio of 0.08, meaning only $0.08 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 10.77, Praxis Precision Medicines, Inc. holds $10.77 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Praxis Precision Medicines, Inc. generated -$131.8M in operating cash flow, capex of $0 consumed most of it, leaving -$131.8M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Praxis Precision Medicines, Inc. passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Praxis Precision Medicines, Inc. generates $0.72 in operating cash flow (-$131.8M OCF vs -$182.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Praxis Precision Medicines, Inc. (PRAX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Praxis Precision Medicines, Inc. generated $8.6M in revenue in fiscal year 2024. This represents an increase of 249.5% from the prior year.
Praxis Precision Medicines, Inc.'s EBITDA was -$199.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 58.7% from the prior year.
Praxis Precision Medicines, Inc. generated -$131.8M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 18.5% from the prior year.
Praxis Precision Medicines, Inc. reported -$182.8M in net income in fiscal year 2024. This represents a decrease of 48.3% from the prior year.
Praxis Precision Medicines, Inc. earned $-10.21 per diluted share (EPS) in fiscal year 2024. This represents an increase of 45.4% from the prior year.
Praxis Precision Medicines, Inc. held $215.4M in cash against $0 in long-term debt as of fiscal year 2024.
Praxis Precision Medicines, Inc. had 19M shares outstanding in fiscal year 2024. This represents an increase of 120.9% from the prior year.
Praxis Precision Medicines, Inc.'s operating margin was -2340.3% in fiscal year 2024, reflecting core business profitability. This is up 2824.1 percentage points from the prior year.
Praxis Precision Medicines, Inc.'s net profit margin was -2137.5% in fiscal year 2024, showing the share of revenue converted to profit. This is up 2900.4 percentage points from the prior year.
Praxis Precision Medicines, Inc. invested $152.4M in research and development in fiscal year 2024. This represents an increase of 75.7% from the prior year.
Praxis Precision Medicines, Inc. invested $0 in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.
PRAX Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0-100.0% | $7.5M+2371.2% | $302K-15.4% | $357K-17.2% | $431K-16.3% | $515K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $65.8M+4.4% | $63.0M+3.6% | $60.8M+8.0% | $56.3M+34.4% | $41.9M+53.6% | $27.3M+1.0% | $27.0M+46.7% | $18.4M |
| SG&A Expenses | $12.6M-3.8% | $13.1M-6.2% | $13.9M-8.0% | $15.1M-0.8% | $15.3M+44.1% | $10.6M-31.0% | $15.3M+54.4% | $9.9M |
| Operating Income | -$78.4M-3.0% | -$76.1M-1.8% | -$74.7M-16.8% | -$64.0M-12.5% | -$56.8M-51.6% | -$37.5M+10.5% | -$41.9M-50.6% | -$27.8M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$73.9M-3.9% | -$71.1M-2.6% | -$69.3M-18.1% | -$58.7M-13.0% | -$51.9M-58.9% | -$32.7M+17.4% | -$39.6M-47.2% | -$26.9M |
| EPS (Diluted) | $-3.36-1.5% | $-3.31-0.6% | $-3.29-14.2% | $-2.88-4.7% | $-2.75-58.0% | $-1.74+38.7% | $-2.84-242.7% | $1.99 |
PRAX Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $396.4M-12.5% | $452.8M-5.4% | $478.7M-0.9% | $483.1M+16.1% | $416.3M-5.6% | $441.1M+76.1% | $250.4M+184.7% | $87.9M |
| Current Assets | $273.8M-10.7% | $306.6M-8.1% | $333.6M-17.5% | $404.4M+12.3% | $360.0M+0.9% | $356.7M+68.4% | $211.8M+149.5% | $84.9M |
| Cash & Equivalents | $149.5M-5.0% | $157.4M-4.9% | $165.6M-23.1% | $215.4M+27.7% | $168.6M+16.2% | $145.1M-4.5% | $152.0M+86.9% | $81.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $52.9M+8.8% | $48.6M+23.0% | $39.5M+4.9% | $37.7M+12.1% | $33.6M+52.9% | $22.0M+6.0% | $20.7M+13.4% | $18.3M |
| Current Liabilities | $52.9M+8.8% | $48.6M+23.0% | $39.5M+5.3% | $37.5M+14.3% | $32.9M+59.4% | $20.6M+9.7% | $18.8M+19.3% | $15.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $343.5M-15.0% | $404.2M-8.0% | $439.2M-1.4% | $445.4M+16.4% | $382.7M-8.7% | $419.1M+82.5% | $229.7M+229.7% | $69.7M |
| Retained Earnings | -$1.1B-7.6% | -$977.2M-7.9% | -$906.0M-8.3% | -$836.7M-7.5% | -$778.1M-7.1% | -$726.2M-4.7% | -$693.5M-6.0% | -$653.9M |
PRAX Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$65.1M-19.0% | -$54.7M-3.1% | -$53.0M+5.5% | -$56.1M-104.1% | -$27.5M-0.8% | -$27.3M-30.8% | -$20.9M+12.6% | -$23.9M |
| Capital Expenditures | $0 | N/A | N/A | $0 | $0 | N/A | N/A | $50K |
| Free Cash Flow | -$65.1M | N/A | N/A | -$56.1M-104.1% | -$27.5M | N/A | N/A | -$23.9M |
| Investing Cash Flow | $50.4M+181.7% | $17.9M+135.0% | -$51.1M-367.7% | -$10.9M-122.0% | $49.6M+125.3% | -$195.9M-114.8% | -$91.2M-182340.0% | -$50K |
| Financing Cash Flow | $6.8M-76.4% | $28.6M-47.2% | $54.3M-52.3% | $113.8M+7822.5% | $1.4M-99.3% | $216.4M+18.4% | $182.8M+4329.4% | $4.1M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PRAX Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | -857.0%+17962.6pp | -18819.5%-8318.7pp | -10500.8%-782.5pp | -9718.3%-4319.1pp | -5399.2% |
| Net Margin | N/A | N/A | N/A | -786.3%+16402.5pp | -17188.7%-8035.5pp | -9153.2%+23.8pp | -9177.0%-3958.0pp | -5219.0% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -18.6%-2.9pp | -15.7%-1.2pp | -14.5%-2.3pp | -12.2%+0.3pp | -12.5%-5.1pp | -7.4%+8.4pp | -15.8%+14.8pp | -30.6% |
| Current Ratio | 5.18-1.1 | 6.31-2.1 | 8.44-2.3 | 10.77-0.2 | 10.96-6.3 | 17.30+6.0 | 11.27+5.9 | 5.39 |
| Debt-to-Equity | 0.15+0.0 | 0.12+0.0 | 0.090.0 | 0.080.0 | 0.09+0.0 | 0.05-0.0 | 0.09-0.2 | 0.26 |
| FCF Margin | N/A | N/A | N/A | -752.0%+8354.0pp | -9106.0% | N/A | N/A | -4642.9% |
Similar Companies
Frequently Asked Questions
What is Praxis Precision Medicines, Inc.'s annual revenue?
Praxis Precision Medicines, Inc. (PRAX) reported $8.6M in total revenue for fiscal year 2024. This represents a 249.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Praxis Precision Medicines, Inc.'s revenue growing?
Praxis Precision Medicines, Inc. (PRAX) revenue grew by 249.5% year-over-year, from $2.4M to $8.6M in fiscal year 2024.
Is Praxis Precision Medicines, Inc. profitable?
No, Praxis Precision Medicines, Inc. (PRAX) reported a net income of -$182.8M in fiscal year 2024, with a net profit margin of -2137.5%.
What is Praxis Precision Medicines, Inc.'s earnings per share (EPS)?
Praxis Precision Medicines, Inc. (PRAX) reported diluted earnings per share of $-10.21 for fiscal year 2024. This represents a 45.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Praxis Precision Medicines, Inc.'s EBITDA?
Praxis Precision Medicines, Inc. (PRAX) had EBITDA of -$199.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Praxis Precision Medicines, Inc.'s operating margin?
Praxis Precision Medicines, Inc. (PRAX) had an operating margin of -2340.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Praxis Precision Medicines, Inc.'s net profit margin?
Praxis Precision Medicines, Inc. (PRAX) had a net profit margin of -2137.5% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Praxis Precision Medicines, Inc.'s free cash flow?
Praxis Precision Medicines, Inc. (PRAX) generated -$131.8M in free cash flow during fiscal year 2024. This represents a -18.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Praxis Precision Medicines, Inc.'s operating cash flow?
Praxis Precision Medicines, Inc. (PRAX) generated -$131.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Praxis Precision Medicines, Inc.'s total assets?
Praxis Precision Medicines, Inc. (PRAX) had $483.1M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Praxis Precision Medicines, Inc.'s capital expenditures?
Praxis Precision Medicines, Inc. (PRAX) invested $0 in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Praxis Precision Medicines, Inc. spend on research and development?
Praxis Precision Medicines, Inc. (PRAX) invested $152.4M in research and development during fiscal year 2024.
How many shares does Praxis Precision Medicines, Inc. have outstanding?
Praxis Precision Medicines, Inc. (PRAX) had 19M shares outstanding as of fiscal year 2024.
What is Praxis Precision Medicines, Inc.'s current ratio?
Praxis Precision Medicines, Inc. (PRAX) had a current ratio of 10.77 as of fiscal year 2024, which is generally considered healthy.
What is Praxis Precision Medicines, Inc.'s debt-to-equity ratio?
Praxis Precision Medicines, Inc. (PRAX) had a debt-to-equity ratio of 0.08 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Praxis Precision Medicines, Inc.'s return on assets (ROA)?
Praxis Precision Medicines, Inc. (PRAX) had a return on assets of -37.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Praxis Precision Medicines, Inc.'s cash runway?
Based on fiscal year 2024 data, Praxis Precision Medicines, Inc. (PRAX) had $215.4M in cash against an annual operating cash burn of $131.8M. This gives an estimated cash runway of approximately 20 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Praxis Precision Medicines, Inc.'s Piotroski F-Score?
Praxis Precision Medicines, Inc. (PRAX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Praxis Precision Medicines, Inc.'s earnings high quality?
Praxis Precision Medicines, Inc. (PRAX) has an earnings quality ratio of 0.72x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Praxis Precision Medicines, Inc.?
Praxis Precision Medicines, Inc. (PRAX) scores 60 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.